Engrail Therapeutics initiates ENX-102 Phase 2 trial in generalized anxiety disorder
Engrail Therapeutics, a neuroscience company committed to advancing transformational therapies, announced the start of a multi-center Phase 2 clinical trial, dubbed the ENCALM trial. The ... Read More